| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystadenocarcinoma, Serous | 41 | 2022 | 497 | 6.680 |
Why?
|
| Ovarian Neoplasms | 95 | 2023 | 4774 | 5.920 |
Why?
|
| Endometrial Neoplasms | 48 | 2023 | 1380 | 5.390 |
Why?
|
| Peritoneal Neoplasms | 26 | 2022 | 851 | 4.840 |
Why?
|
| Carcinoma, Endometrioid | 24 | 2023 | 329 | 4.290 |
Why?
|
| Fallopian Tube Neoplasms | 9 | 2022 | 155 | 3.090 |
Why?
|
| Uterine Neoplasms | 25 | 2022 | 580 | 2.850 |
Why?
|
| Uterine Cervical Neoplasms | 57 | 2023 | 1913 | 2.560 |
Why?
|
| Vulvar Neoplasms | 16 | 2021 | 236 | 1.920 |
Why?
|
| Uterine Cervical Dysplasia | 34 | 2012 | 222 | 1.760 |
Why?
|
| Immunohistochemistry | 62 | 2022 | 7812 | 1.660 |
Why?
|
| Mesothelioma | 5 | 2022 | 557 | 1.590 |
Why?
|
| Carcinoma | 15 | 2023 | 2619 | 1.550 |
Why?
|
| Neoplasms, Multiple Primary | 15 | 2014 | 559 | 1.320 |
Why?
|
| Biomarkers, Tumor | 54 | 2022 | 10694 | 1.240 |
Why?
|
| Female | 256 | 2023 | 148552 | 1.200 |
Why?
|
| Leiomyosarcoma | 6 | 2020 | 255 | 1.170 |
Why?
|
| Cervix Uteri | 19 | 2012 | 252 | 1.020 |
Why?
|
| Carcinosarcoma | 5 | 2019 | 148 | 0.980 |
Why?
|
| Adenocarcinoma | 20 | 2023 | 7934 | 0.960 |
Why?
|
| Papillomaviridae | 9 | 2021 | 642 | 0.940 |
Why?
|
| Endometriosis | 3 | 2023 | 235 | 0.910 |
Why?
|
| Adult | 130 | 2023 | 81579 | 0.900 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 6 | 2017 | 107 | 0.900 |
Why?
|
| Mesonephroma | 1 | 2023 | 18 | 0.880 |
Why?
|
| Sarcoma, Endometrial Stromal | 6 | 2015 | 15 | 0.860 |
Why?
|
| Middle Aged | 118 | 2023 | 90054 | 0.850 |
Why?
|
| Humans | 261 | 2023 | 270832 | 0.840 |
Why?
|
| Asbestos | 1 | 2022 | 35 | 0.820 |
Why?
|
| Neoplasm Grading | 19 | 2022 | 1820 | 0.800 |
Why?
|
| Lymphatic Metastasis | 16 | 2021 | 4967 | 0.800 |
Why?
|
| Endometrial Hyperplasia | 4 | 2020 | 117 | 0.790 |
Why?
|
| Cysts | 2 | 2022 | 208 | 0.790 |
Why?
|
| Neoplasm Recurrence, Local | 32 | 2022 | 10352 | 0.780 |
Why?
|
| Sentinel Lymph Node | 4 | 2021 | 229 | 0.760 |
Why?
|
| Wolffian Ducts | 2 | 2020 | 24 | 0.760 |
Why?
|
| Carcinoma, Neuroendocrine | 5 | 2021 | 741 | 0.760 |
Why?
|
| Neoplasm Staging | 49 | 2022 | 13979 | 0.750 |
Why?
|
| Aged | 90 | 2023 | 73214 | 0.750 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2021 | 31 | 0.750 |
Why?
|
| Teratoma | 4 | 2015 | 253 | 0.700 |
Why?
|
| Diagnosis, Differential | 30 | 2022 | 4888 | 0.700 |
Why?
|
| Papillomavirus Infections | 10 | 2021 | 1009 | 0.690 |
Why?
|
| PAX8 Transcription Factor | 2 | 2016 | 57 | 0.680 |
Why?
|
| Hysterectomy | 12 | 2021 | 645 | 0.670 |
Why?
|
| Ovary | 10 | 2020 | 701 | 0.660 |
Why?
|
| Adenocarcinoma, Clear Cell | 5 | 2011 | 183 | 0.640 |
Why?
|
| Adenocarcinoma, Mucinous | 4 | 2020 | 441 | 0.610 |
Why?
|
| Practice Guidelines as Topic | 9 | 2021 | 2428 | 0.600 |
Why?
|
| Aged, 80 and over | 44 | 2021 | 30953 | 0.590 |
Why?
|
| Cystadenoma, Serous | 4 | 2013 | 31 | 0.590 |
Why?
|
| Endometrium | 5 | 2020 | 469 | 0.570 |
Why?
|
| Peritoneum | 5 | 2022 | 150 | 0.570 |
Why?
|
| Cystadenoma, Mucinous | 2 | 2009 | 35 | 0.550 |
Why?
|
| Vulva | 3 | 2015 | 38 | 0.540 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2020 | 458 | 0.540 |
Why?
|
| Exocrine Glands | 1 | 2015 | 16 | 0.520 |
Why?
|
| Lymph Nodes | 8 | 2019 | 3067 | 0.520 |
Why?
|
| Gynecology | 9 | 2021 | 232 | 0.520 |
Why?
|
| Immunoenzyme Techniques | 12 | 2009 | 1209 | 0.510 |
Why?
|
| Vaginal Neoplasms | 7 | 2014 | 155 | 0.500 |
Why?
|
| Biopsy | 17 | 2022 | 3543 | 0.500 |
Why?
|
| Carcinoma, Squamous Cell | 13 | 2020 | 5566 | 0.500 |
Why?
|
| Pathologists | 9 | 2022 | 101 | 0.500 |
Why?
|
| Gynecologic Surgical Procedures | 9 | 2016 | 378 | 0.460 |
Why?
|
| Disease-Free Survival | 21 | 2023 | 10249 | 0.430 |
Why?
|
| Colorectal Neoplasms | 3 | 2020 | 3661 | 0.430 |
Why?
|
| Cell Nucleus | 12 | 2013 | 1740 | 0.430 |
Why?
|
| Endodermal Sinus Tumor | 3 | 2017 | 50 | 0.420 |
Why?
|
| Smooth Muscle Tumor | 2 | 2009 | 15 | 0.420 |
Why?
|
| Cystadenocarcinoma, Papillary | 6 | 2022 | 83 | 0.420 |
Why?
|
| Lymphangioma | 2 | 2003 | 35 | 0.420 |
Why?
|
| Carcinoma in Situ | 10 | 2015 | 495 | 0.420 |
Why?
|
| Chemotherapy, Adjuvant | 9 | 2021 | 3972 | 0.420 |
Why?
|
| Lymph Node Excision | 9 | 2021 | 2044 | 0.410 |
Why?
|
| Mitotic Index | 7 | 2016 | 166 | 0.410 |
Why?
|
| Young Adult | 26 | 2022 | 22052 | 0.410 |
Why?
|
| Prognosis | 36 | 2019 | 22462 | 0.400 |
Why?
|
| Carcinoma, Small Cell | 4 | 2021 | 425 | 0.400 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2021 | 3653 | 0.390 |
Why?
|
| Hormones | 2 | 2003 | 292 | 0.390 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2017 | 2468 | 0.390 |
Why?
|
| Dermatofibrosarcoma | 2 | 2010 | 73 | 0.380 |
Why?
|
| Uterine Cervical Diseases | 5 | 2006 | 24 | 0.380 |
Why?
|
| Neoadjuvant Therapy | 4 | 2021 | 5206 | 0.360 |
Why?
|
| Nevus, Blue | 1 | 2010 | 40 | 0.360 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2015 | 693 | 0.360 |
Why?
|
| Precancerous Conditions | 11 | 2012 | 1065 | 0.360 |
Why?
|
| Retroperitoneal Neoplasms | 2 | 2012 | 299 | 0.360 |
Why?
|
| Societies, Medical | 10 | 2021 | 1348 | 0.360 |
Why?
|
| Microscopy, Confocal | 8 | 2007 | 674 | 0.330 |
Why?
|
| Colposcopy | 10 | 2011 | 75 | 0.330 |
Why?
|
| Cystadenocarcinoma, Mucinous | 1 | 2009 | 22 | 0.330 |
Why?
|
| Neoplasm Invasiveness | 11 | 2020 | 4069 | 0.330 |
Why?
|
| Neoplasm Proteins | 11 | 2013 | 3343 | 0.320 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 15 | 2021 | 16600 | 0.320 |
Why?
|
| Diagnostic Errors | 2 | 2011 | 531 | 0.320 |
Why?
|
| Stomach Neoplasms | 1 | 2021 | 2316 | 0.310 |
Why?
|
| Submandibular Gland Neoplasms | 1 | 2008 | 38 | 0.310 |
Why?
|
| Retrospective Studies | 37 | 2022 | 39703 | 0.310 |
Why?
|
| Predictive Value of Tests | 11 | 2022 | 4981 | 0.300 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 2008 | 36 | 0.300 |
Why?
|
| Skin Neoplasms | 4 | 2010 | 4838 | 0.290 |
Why?
|
| Ki-67 Antigen | 6 | 2013 | 685 | 0.290 |
Why?
|
| Combined Modality Therapy | 18 | 2013 | 9041 | 0.290 |
Why?
|
| Myofibroblasts | 2 | 2022 | 103 | 0.290 |
Why?
|
| Granulosa Cell Tumor | 3 | 2022 | 81 | 0.280 |
Why?
|
| Neoplasm Regression, Spontaneous | 3 | 2011 | 39 | 0.280 |
Why?
|
| Fallopian Tubes | 3 | 2022 | 131 | 0.280 |
Why?
|
| Hemangiosarcoma | 1 | 2009 | 237 | 0.280 |
Why?
|
| Germ-Line Mutation | 2 | 2022 | 1069 | 0.280 |
Why?
|
| CA-125 Antigen | 2 | 2007 | 228 | 0.270 |
Why?
|
| Treatment Outcome | 17 | 2022 | 33837 | 0.270 |
Why?
|
| Microsatellite Instability | 3 | 2016 | 409 | 0.270 |
Why?
|
| Time Factors | 10 | 2020 | 13107 | 0.270 |
Why?
|
| S100 Calcium Binding Protein G | 6 | 2012 | 53 | 0.260 |
Why?
|
| Spectrometry, Fluorescence | 9 | 2011 | 207 | 0.260 |
Why?
|
| Carcinoid Tumor | 1 | 2007 | 281 | 0.260 |
Why?
|
| MutS Homolog 2 Protein | 2 | 2022 | 172 | 0.250 |
Why?
|
| Melanoma | 7 | 2016 | 5525 | 0.230 |
Why?
|
| Statistics as Topic | 1 | 2005 | 451 | 0.230 |
Why?
|
| Laparoscopy | 4 | 2020 | 1292 | 0.230 |
Why?
|
| Adolescent | 22 | 2022 | 32534 | 0.230 |
Why?
|
| Lymphatic Diseases | 1 | 2004 | 130 | 0.230 |
Why?
|
| Endometrial Stromal Tumors | 2 | 2013 | 7 | 0.220 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 4 | 2004 | 38 | 0.220 |
Why?
|
| Neoplasms, Second Primary | 5 | 2006 | 1379 | 0.220 |
Why?
|
| Cohort Studies | 5 | 2022 | 9434 | 0.220 |
Why?
|
| Dynamin III | 1 | 2022 | 3 | 0.220 |
Why?
|
| Calbindin 2 | 6 | 2012 | 43 | 0.220 |
Why?
|
| Mutation | 9 | 2022 | 15850 | 0.220 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2020 | 1406 | 0.210 |
Why?
|
| Ischium | 1 | 2002 | 11 | 0.210 |
Why?
|
| Cystadenocarcinoma | 2 | 2001 | 25 | 0.210 |
Why?
|
| Premenopause | 4 | 2020 | 139 | 0.210 |
Why?
|
| Disease Progression | 8 | 2020 | 6895 | 0.210 |
Why?
|
| Dystocia | 1 | 2002 | 24 | 0.210 |
Why?
|
| Telomerase | 2 | 2022 | 530 | 0.210 |
Why?
|
| Peritoneal Diseases | 1 | 2002 | 33 | 0.200 |
Why?
|
| Diagnosis, Computer-Assisted | 4 | 2012 | 169 | 0.200 |
Why?
|
| Neoplasms, Connective Tissue | 1 | 2022 | 20 | 0.200 |
Why?
|
| Image Interpretation, Computer-Assisted | 4 | 2008 | 592 | 0.200 |
Why?
|
| Choristoma | 1 | 2002 | 87 | 0.200 |
Why?
|
| Polyploidy | 1 | 2022 | 78 | 0.200 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2002 | 102 | 0.200 |
Why?
|
| Epithelioid Cells | 1 | 2022 | 43 | 0.200 |
Why?
|
| Ovariectomy | 4 | 2016 | 372 | 0.190 |
Why?
|
| DNA-Binding Proteins | 7 | 2008 | 5037 | 0.190 |
Why?
|
| Decidua | 1 | 2002 | 155 | 0.190 |
Why?
|
| Pathology, Clinical | 1 | 2022 | 154 | 0.190 |
Why?
|
| Survival Analysis | 7 | 2020 | 9304 | 0.190 |
Why?
|
| Carcinoma, Large Cell | 1 | 2021 | 96 | 0.180 |
Why?
|
| Leiomyoma | 4 | 2020 | 161 | 0.180 |
Why?
|
| Keratins | 5 | 2013 | 351 | 0.180 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2002 | 235 | 0.180 |
Why?
|
| Prophylactic Surgical Procedures | 1 | 2020 | 24 | 0.180 |
Why?
|
| Salpingo-oophorectomy | 1 | 2020 | 50 | 0.180 |
Why?
|
| Fatal Outcome | 3 | 2009 | 835 | 0.180 |
Why?
|
| Paget Disease, Extramammary | 2 | 2015 | 54 | 0.180 |
Why?
|
| Tomography, Optical Coherence | 1 | 2005 | 544 | 0.180 |
Why?
|
| Genital Neoplasms, Female | 3 | 2020 | 790 | 0.180 |
Why?
|
| Image Cytometry | 4 | 2004 | 46 | 0.180 |
Why?
|
| Follow-Up Studies | 14 | 2020 | 15241 | 0.170 |
Why?
|
| Homozygote | 1 | 2022 | 759 | 0.170 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2022 | 508 | 0.170 |
Why?
|
| Antineoplastic Agents | 13 | 2021 | 14651 | 0.170 |
Why?
|
| Survival Rate | 14 | 2017 | 12516 | 0.170 |
Why?
|
| Melanoma-Specific Antigens | 3 | 2004 | 85 | 0.170 |
Why?
|
| Fenretinide | 3 | 2005 | 100 | 0.170 |
Why?
|
| Calcinosis | 1 | 2003 | 431 | 0.170 |
Why?
|
| Inhibins | 4 | 2004 | 126 | 0.170 |
Why?
|
| Fibrosis | 1 | 2002 | 746 | 0.170 |
Why?
|
| Integrases | 1 | 2020 | 266 | 0.170 |
Why?
|
| Salpingectomy | 2 | 2016 | 46 | 0.160 |
Why?
|
| Sequence Deletion | 1 | 2022 | 909 | 0.160 |
Why?
|
| Pathology, Molecular | 2 | 2019 | 124 | 0.160 |
Why?
|
| Myometrium | 2 | 2013 | 83 | 0.160 |
Why?
|
| Spectrum Analysis | 3 | 2011 | 144 | 0.160 |
Why?
|
| Epithelium | 5 | 2011 | 804 | 0.160 |
Why?
|
| Nuclear Proteins | 3 | 2023 | 3455 | 0.150 |
Why?
|
| Postmenopause | 3 | 2005 | 380 | 0.150 |
Why?
|
| Algorithms | 10 | 2010 | 3904 | 0.150 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2016 | 1329 | 0.150 |
Why?
|
| Abdominal Wall | 1 | 2020 | 192 | 0.150 |
Why?
|
| Histocytochemistry | 2 | 2010 | 206 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2011 | 505 | 0.140 |
Why?
|
| Cell Differentiation | 5 | 2015 | 4190 | 0.140 |
Why?
|
| Neurocytoma | 1 | 2016 | 17 | 0.140 |
Why?
|
| Rhabdomyosarcoma | 2 | 2000 | 342 | 0.140 |
Why?
|
| Eflornithine | 3 | 2005 | 61 | 0.140 |
Why?
|
| Epithelial Cells | 5 | 2010 | 1888 | 0.140 |
Why?
|
| Sarcoma | 3 | 2015 | 1839 | 0.140 |
Why?
|
| Reproducibility of Results | 11 | 2012 | 6187 | 0.140 |
Why?
|
| Sensitivity and Specificity | 15 | 2011 | 5186 | 0.130 |
Why?
|
| Repressor Proteins | 2 | 2023 | 1725 | 0.130 |
Why?
|
| Receptors, Progesterone | 4 | 2012 | 1646 | 0.130 |
Why?
|
| Risk | 1 | 2020 | 1913 | 0.130 |
Why?
|
| Anticarcinogenic Agents | 4 | 2005 | 371 | 0.130 |
Why?
|
| Histones | 3 | 2013 | 1512 | 0.130 |
Why?
|
| Urogenital Neoplasms | 1 | 2017 | 115 | 0.130 |
Why?
|
| Vulvar Lichen Sclerosus | 1 | 2015 | 7 | 0.130 |
Why?
|
| Paired Box Transcription Factors | 1 | 2016 | 133 | 0.130 |
Why?
|
| Observer Variation | 3 | 2007 | 720 | 0.130 |
Why?
|
| Maintenance Chemotherapy | 1 | 2017 | 224 | 0.130 |
Why?
|
| Carcinoma, Papillary | 2 | 2010 | 580 | 0.130 |
Why?
|
| Receptors, Estrogen | 5 | 2012 | 2263 | 0.130 |
Why?
|
| Breast Neoplasms | 8 | 2015 | 16188 | 0.130 |
Why?
|
| Keratin-5 | 2 | 2012 | 57 | 0.120 |
Why?
|
| Keratin-6 | 2 | 2012 | 40 | 0.120 |
Why?
|
| Terminology as Topic | 2 | 2010 | 419 | 0.120 |
Why?
|
| Mesothelioma, Cystic | 2 | 2005 | 3 | 0.120 |
Why?
|
| Alleles | 1 | 2021 | 2506 | 0.120 |
Why?
|
| Glioma | 2 | 2016 | 1969 | 0.120 |
Why?
|
| Watchful Waiting | 1 | 2017 | 292 | 0.120 |
Why?
|
| Cell Shape | 2 | 2013 | 129 | 0.120 |
Why?
|
| Cell Size | 2 | 2013 | 145 | 0.120 |
Why?
|
| In Situ Hybridization | 3 | 2011 | 1062 | 0.120 |
Why?
|
| DNA Mismatch Repair | 1 | 2016 | 276 | 0.120 |
Why?
|
| Texas | 7 | 2019 | 6412 | 0.120 |
Why?
|
| Trophoblastic Neoplasms | 2 | 2009 | 19 | 0.120 |
Why?
|
| Mammary Glands, Human | 1 | 2015 | 185 | 0.120 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 1070 | 0.120 |
Why?
|
| Risk Factors | 14 | 2020 | 17819 | 0.120 |
Why?
|
| Dysgerminoma | 1 | 2014 | 42 | 0.120 |
Why?
|
| DNA, Neoplasm | 6 | 2013 | 1959 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-kit | 3 | 2005 | 490 | 0.110 |
Why?
|
| Microsatellite Repeats | 3 | 2006 | 613 | 0.110 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 2337 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 9 | 2 | 2005 | 290 | 0.110 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 2 | 2004 | 41 | 0.110 |
Why?
|
| MART-1 Antigen | 2 | 2004 | 113 | 0.110 |
Why?
|
| Monophenol Monooxygenase | 2 | 2004 | 59 | 0.110 |
Why?
|
| Scattering, Radiation | 5 | 2005 | 334 | 0.110 |
Why?
|
| Cell Nucleus Size | 1 | 2013 | 2 | 0.110 |
Why?
|
| Leukemia, Plasma Cell | 1 | 1993 | 43 | 0.110 |
Why?
|
| Antibodies | 1 | 2016 | 819 | 0.110 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2016 | 562 | 0.110 |
Why?
|
| S100 Proteins | 2 | 2004 | 190 | 0.110 |
Why?
|
| Cystadenoma | 2 | 2010 | 29 | 0.110 |
Why?
|
| Megestrol Acetate | 2 | 2003 | 31 | 0.110 |
Why?
|
| Neovascularization, Pathologic | 2 | 2015 | 1598 | 0.110 |
Why?
|
| Prostatic Hyperplasia | 1 | 1994 | 222 | 0.110 |
Why?
|
| Neoplasm Metastasis | 4 | 2015 | 5325 | 0.110 |
Why?
|
| Genes, ras | 1 | 2016 | 679 | 0.110 |
Why?
|
| Guinea Pigs | 2 | 2003 | 253 | 0.110 |
Why?
|
| Antigens, Neoplasm | 3 | 2004 | 1588 | 0.110 |
Why?
|
| Liver Neoplasms | 2 | 2007 | 4795 | 0.100 |
Why?
|
| Condoms | 1 | 2012 | 48 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2013 | 2610 | 0.100 |
Why?
|
| Desmin | 4 | 2012 | 64 | 0.100 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2015 | 343 | 0.100 |
Why?
|
| Chorionic Gonadotropin | 2 | 2003 | 134 | 0.100 |
Why?
|
| Hemangioma | 1 | 2014 | 160 | 0.100 |
Why?
|
| Microscopy, Fluorescence | 4 | 2002 | 781 | 0.100 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2012 | 848 | 0.100 |
Why?
|
| Age Factors | 6 | 2016 | 5486 | 0.100 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2002 | 2437 | 0.100 |
Why?
|
| Image Enhancement | 3 | 2008 | 555 | 0.100 |
Why?
|
| Menopause | 1 | 2012 | 160 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 10 | 2013 | 1707 | 0.090 |
Why?
|
| Retinoblastoma-Like Protein p130 | 1 | 2010 | 17 | 0.090 |
Why?
|
| Kidney Neoplasms | 2 | 2023 | 3146 | 0.090 |
Why?
|
| Phytohemagglutinins | 1 | 2010 | 73 | 0.090 |
Why?
|
| Sentinel Lymph Node Biopsy | 3 | 2009 | 1449 | 0.090 |
Why?
|
| Acetylglucosamine | 1 | 2010 | 26 | 0.090 |
Why?
|
| Collagen | 3 | 2003 | 737 | 0.090 |
Why?
|
| Urethral Neoplasms | 2 | 2004 | 64 | 0.090 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2010 | 48 | 0.090 |
Why?
|
| Lectins | 1 | 2010 | 152 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2013 | 2266 | 0.090 |
Why?
|
| Aorta, Abdominal | 1 | 2011 | 150 | 0.090 |
Why?
|
| WT1 Proteins | 3 | 2005 | 107 | 0.090 |
Why?
|
| Tamoxifen | 3 | 2017 | 906 | 0.090 |
Why?
|
| Prostheses and Implants | 1 | 2012 | 296 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2016 | 6251 | 0.090 |
Why?
|
| Platinum Compounds | 3 | 2017 | 127 | 0.090 |
Why?
|
| PAX2 Transcription Factor | 1 | 2009 | 43 | 0.080 |
Why?
|
| Bone Neoplasms | 1 | 2002 | 2667 | 0.080 |
Why?
|
| Remission Induction | 3 | 2016 | 3645 | 0.080 |
Why?
|
| ras Proteins | 1 | 2013 | 801 | 0.080 |
Why?
|
| DNA, Viral | 3 | 2010 | 763 | 0.080 |
Why?
|
| Actins | 4 | 2012 | 616 | 0.080 |
Why?
|
| Pelvis | 1 | 2011 | 384 | 0.080 |
Why?
|
| Carrier Proteins | 2 | 2011 | 2120 | 0.080 |
Why?
|
| Child, Preschool | 4 | 2021 | 16925 | 0.080 |
Why?
|
| Fallopian Tube Diseases | 1 | 2008 | 19 | 0.080 |
Why?
|
| Ifosfamide | 1 | 2009 | 357 | 0.080 |
Why?
|
| Teratocarcinoma | 1 | 2008 | 24 | 0.080 |
Why?
|
| Testosterone | 3 | 2003 | 733 | 0.080 |
Why?
|
| Equipment Design | 3 | 2011 | 1206 | 0.080 |
Why?
|
| Oral Surgical Procedures | 1 | 2008 | 33 | 0.080 |
Why?
|
| Stromal Cells | 1 | 2012 | 835 | 0.080 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2011 | 638 | 0.080 |
Why?
|
| Artifacts | 2 | 2009 | 536 | 0.080 |
Why?
|
| Colonic Diseases | 1 | 2008 | 74 | 0.080 |
Why?
|
| Staining and Labeling | 3 | 2004 | 465 | 0.080 |
Why?
|
| Transcription Factors | 4 | 2008 | 5489 | 0.080 |
Why?
|
| Trophoblasts | 1 | 2009 | 150 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 2397 | 0.080 |
Why?
|
| Fiber Optic Technology | 3 | 2003 | 145 | 0.070 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2008 | 92 | 0.070 |
Why?
|
| Blood Vessels | 1 | 2009 | 239 | 0.070 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2008 | 106 | 0.070 |
Why?
|
| Lung Neoplasms | 3 | 2020 | 11774 | 0.070 |
Why?
|
| Tissue Embedding | 2 | 2004 | 29 | 0.070 |
Why?
|
| Tumor Burden | 1 | 2013 | 2034 | 0.070 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2007 | 21 | 0.070 |
Why?
|
| Pattern Recognition, Automated | 1 | 2008 | 125 | 0.070 |
Why?
|
| Child | 5 | 2021 | 30366 | 0.070 |
Why?
|
| Models, Biological | 3 | 2005 | 3221 | 0.070 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2008 | 209 | 0.070 |
Why?
|
| Lasers | 3 | 1996 | 238 | 0.070 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2006 | 85 | 0.070 |
Why?
|
| Polyps | 2 | 2005 | 82 | 0.070 |
Why?
|
| DNA Sequence, Unstable | 1 | 2006 | 7 | 0.070 |
Why?
|
| Pilot Projects | 4 | 2009 | 2851 | 0.070 |
Why?
|
| Leuprolide | 2 | 2017 | 67 | 0.070 |
Why?
|
| Intestinal Obstruction | 1 | 2008 | 224 | 0.070 |
Why?
|
| Fluorescence | 2 | 2003 | 199 | 0.070 |
Why?
|
| Pelvic Neoplasms | 1 | 2007 | 203 | 0.070 |
Why?
|
| Logistic Models | 4 | 2013 | 3428 | 0.070 |
Why?
|
| Artificial Intelligence | 3 | 2008 | 430 | 0.070 |
Why?
|
| Cell Proliferation | 3 | 2013 | 7291 | 0.070 |
Why?
|
| Membrane Glycoproteins | 1 | 2010 | 1100 | 0.070 |
Why?
|
| Histological Techniques | 1 | 2005 | 65 | 0.060 |
Why?
|
| Robotics | 1 | 2009 | 365 | 0.060 |
Why?
|
| Abdominal Neoplasms | 1 | 2007 | 249 | 0.060 |
Why?
|
| Animals | 8 | 2020 | 62749 | 0.060 |
Why?
|
| Age of Onset | 1 | 2007 | 823 | 0.060 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2008 | 285 | 0.060 |
Why?
|
| Proportional Hazards Models | 4 | 2016 | 5087 | 0.060 |
Why?
|
| Reoperation | 1 | 2010 | 1389 | 0.060 |
Why?
|
| NAD | 2 | 2003 | 88 | 0.060 |
Why?
|
| Chromatin | 3 | 2005 | 1048 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 1177 | 0.060 |
Why?
|
| Cadherins | 1 | 2007 | 676 | 0.060 |
Why?
|
| Aneuploidy | 1 | 2005 | 377 | 0.060 |
Why?
|
| Superantigens | 1 | 2004 | 32 | 0.060 |
Why?
|
| Mucin-1 | 1 | 2004 | 164 | 0.060 |
Why?
|
| Cyclin E | 1 | 2006 | 283 | 0.060 |
Why?
|
| Gene Rearrangement | 1 | 2008 | 817 | 0.060 |
Why?
|
| Optics and Photonics | 1 | 2005 | 163 | 0.060 |
Why?
|
| Gold Colloid | 1 | 2003 | 3 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 3646 | 0.060 |
Why?
|
| Receptor, ErbB-2 | 3 | 2013 | 2646 | 0.060 |
Why?
|
| Pathology | 1 | 2004 | 108 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2003 | 83 | 0.050 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2008 | 521 | 0.050 |
Why?
|
| Clomiphene | 1 | 2003 | 16 | 0.050 |
Why?
|
| Estrone | 1 | 2003 | 35 | 0.050 |
Why?
|
| Norway | 2 | 2013 | 42 | 0.050 |
Why?
|
| SOXF Transcription Factors | 1 | 2023 | 30 | 0.050 |
Why?
|
| Langerhans Cells | 1 | 2003 | 54 | 0.050 |
Why?
|
| Vaginal Smears | 4 | 2005 | 183 | 0.050 |
Why?
|
| Norethindrone | 1 | 2002 | 16 | 0.050 |
Why?
|
| Dihydrotestosterone | 1 | 2003 | 116 | 0.050 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2003 | 154 | 0.050 |
Why?
|
| Genital Diseases, Female | 1 | 2003 | 61 | 0.050 |
Why?
|
| Prolactin | 1 | 2003 | 174 | 0.050 |
Why?
|
| Prostatic Neoplasms | 2 | 2004 | 5975 | 0.050 |
Why?
|
| Th1 Cells | 1 | 2004 | 260 | 0.050 |
Why?
|
| Genotype | 3 | 2020 | 4108 | 0.050 |
Why?
|
| Tissue Array Analysis | 3 | 2011 | 759 | 0.050 |
Why?
|
| Growth Hormone | 1 | 2003 | 227 | 0.050 |
Why?
|
| Luteinizing Hormone | 1 | 2002 | 186 | 0.050 |
Why?
|
| DNA Mutational Analysis | 3 | 2016 | 2350 | 0.050 |
Why?
|
| Adenofibroma | 1 | 2002 | 20 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2009 | 3131 | 0.050 |
Why?
|
| Pregnancy | 5 | 2002 | 8088 | 0.050 |
Why?
|
| ErbB Receptors | 2 | 2003 | 2377 | 0.050 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2002 | 198 | 0.050 |
Why?
|
| RNA-Binding Proteins | 1 | 2008 | 1018 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2011 | 9069 | 0.050 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2007 | 917 | 0.050 |
Why?
|
| Gene Expression Profiling | 5 | 2011 | 5156 | 0.050 |
Why?
|
| Necrosis | 2 | 2013 | 604 | 0.050 |
Why?
|
| Thyroid Diseases | 1 | 2002 | 89 | 0.050 |
Why?
|
| Receptors, Growth Factor | 2 | 2002 | 159 | 0.050 |
Why?
|
| Merkel cell polyomavirus | 1 | 2021 | 31 | 0.050 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2002 | 160 | 0.050 |
Why?
|
| ROC Curve | 3 | 2011 | 1237 | 0.050 |
Why?
|
| Trachelectomy | 1 | 2021 | 33 | 0.050 |
Why?
|
| Ribonuclease III | 1 | 2022 | 188 | 0.050 |
Why?
|
| Cell Count | 2 | 2012 | 524 | 0.050 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2004 | 703 | 0.050 |
Why?
|
| Male | 11 | 2022 | 128425 | 0.050 |
Why?
|
| World Health Organization | 2 | 2013 | 328 | 0.050 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2008 | 1011 | 0.050 |
Why?
|
| Mass Screening | 8 | 2011 | 1544 | 0.050 |
Why?
|
| Epigenomics | 1 | 2022 | 267 | 0.050 |
Why?
|
| Proteomics | 2 | 2022 | 1435 | 0.050 |
Why?
|
| Hyperandrogenism | 1 | 2000 | 20 | 0.040 |
Why?
|
| Cytoskeletal Proteins | 1 | 2003 | 541 | 0.040 |
Why?
|
| Acetic Acid | 1 | 2000 | 33 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 5 | 2009 | 4494 | 0.040 |
Why?
|
| Pelvic Exenteration | 1 | 2021 | 112 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 1996 | 4125 | 0.040 |
Why?
|
| Ultraviolet Rays | 1 | 2002 | 588 | 0.040 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2022 | 262 | 0.040 |
Why?
|
| Baltimore | 1 | 2019 | 22 | 0.040 |
Why?
|
| Neuroectodermal Tumors | 1 | 2000 | 33 | 0.040 |
Why?
|
| Camptothecin | 1 | 2003 | 538 | 0.040 |
Why?
|
| Aromatase Inhibitors | 1 | 2022 | 314 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2006 | 1108 | 0.040 |
Why?
|
| RNA, Messenger | 3 | 2022 | 6478 | 0.040 |
Why?
|
| Glioblastoma | 1 | 2010 | 1778 | 0.040 |
Why?
|
| Rosaniline Dyes | 2 | 2004 | 109 | 0.040 |
Why?
|
| Blotting, Western | 3 | 2011 | 3644 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2003 | 731 | 0.040 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2003 | 284 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2005 | 1327 | 0.040 |
Why?
|
| Genomics | 2 | 2022 | 2817 | 0.040 |
Why?
|
| Immunoconjugates | 1 | 2003 | 314 | 0.040 |
Why?
|
| Monitoring, Intraoperative | 1 | 2021 | 264 | 0.040 |
Why?
|
| Estradiol | 1 | 2003 | 882 | 0.040 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2021 | 172 | 0.040 |
Why?
|
| Intestinal Neoplasms | 1 | 2001 | 201 | 0.040 |
Why?
|
| Uterine Cervicitis | 4 | 2003 | 7 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 1545 | 0.040 |
Why?
|
| Ploidies | 1 | 2019 | 257 | 0.040 |
Why?
|
| Estrogens | 1 | 2002 | 844 | 0.040 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2001 | 331 | 0.040 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2011 | 202 | 0.040 |
Why?
|
| Bevacizumab | 1 | 2021 | 957 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2004 | 2022 | 0.040 |
Why?
|
| Cell Adhesion Molecules | 1 | 2000 | 581 | 0.040 |
Why?
|
| Incidence | 3 | 2016 | 5838 | 0.040 |
Why?
|
| Laser Therapy | 1 | 2002 | 465 | 0.040 |
Why?
|
| Survivors | 1 | 2022 | 1023 | 0.040 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2017 | 50 | 0.040 |
Why?
|
| Reference Values | 3 | 2004 | 1153 | 0.040 |
Why?
|
| Paraffin Embedding | 2 | 2010 | 226 | 0.040 |
Why?
|
| Hepatocyte Growth Factor | 1 | 1997 | 154 | 0.040 |
Why?
|
| Hydatidiform Mole | 1 | 1996 | 39 | 0.030 |
Why?
|
| Etoposide | 2 | 1996 | 905 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2003 | 1655 | 0.030 |
Why?
|
| Mouth Neoplasms | 1 | 2002 | 732 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 3 | 2010 | 3490 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 2671 | 0.030 |
Why?
|
| Sarcoma, Ewing | 1 | 2000 | 426 | 0.030 |
Why?
|
| Leiomyomatosis | 1 | 1995 | 13 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 3 | 2013 | 5802 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 1993 | 5234 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 1057 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 2 | 2004 | 1037 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2002 | 1468 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2020 | 887 | 0.030 |
Why?
|
| Cytoplasm | 3 | 2003 | 718 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2020 | 1014 | 0.030 |
Why?
|
| Multivariate Analysis | 4 | 2013 | 4330 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2011 | 2455 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2000 | 1432 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2021 | 1588 | 0.030 |
Why?
|
| Cytokines | 1 | 2004 | 2835 | 0.030 |
Why?
|
| Nocardia Infections | 1 | 1995 | 36 | 0.030 |
Why?
|
| Epidermolysis Bullosa | 1 | 1994 | 6 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 1435 | 0.030 |
Why?
|
| Papanicolaou Test | 2 | 2005 | 130 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2015 | 354 | 0.030 |
Why?
|
| Acid Phosphatase | 1 | 1994 | 58 | 0.030 |
Why?
|
| Keratin-7 | 2 | 2004 | 50 | 0.030 |
Why?
|
| Placebos | 2 | 2005 | 446 | 0.030 |
Why?
|
| Internet | 1 | 2019 | 697 | 0.030 |
Why?
|
| Urethral Diseases | 1 | 1994 | 39 | 0.030 |
Why?
|
| Microtomy | 2 | 2004 | 16 | 0.030 |
Why?
|
| Soft Tissue Infections | 1 | 1995 | 94 | 0.030 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2013 | 32 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2000 | 1067 | 0.030 |
Why?
|
| Hematoxylin | 1 | 2013 | 34 | 0.030 |
Why?
|
| Ontario | 1 | 2013 | 98 | 0.030 |
Why?
|
| Republic of Korea | 1 | 2013 | 76 | 0.030 |
Why?
|
| Uterus | 1 | 2019 | 811 | 0.030 |
Why?
|
| Thyroglossal Cyst | 1 | 1993 | 14 | 0.030 |
Why?
|
| Facial Paralysis | 1 | 1993 | 58 | 0.030 |
Why?
|
| Hamartoma | 1 | 1994 | 87 | 0.030 |
Why?
|
| Genes, BRCA2 | 1 | 2015 | 310 | 0.030 |
Why?
|
| Deafness | 1 | 1993 | 85 | 0.030 |
Why?
|
| Mexico | 1 | 2013 | 274 | 0.030 |
Why?
|
| Larynx | 1 | 1994 | 144 | 0.030 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2000 | 1233 | 0.030 |
Why?
|
| Aspergillus fumigatus | 1 | 1993 | 138 | 0.030 |
Why?
|
| Genes, BRCA1 | 1 | 2015 | 388 | 0.030 |
Why?
|
| Paclitaxel | 2 | 2015 | 2099 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2013 | 187 | 0.030 |
Why?
|
| Mice, Nude | 2 | 2010 | 4356 | 0.030 |
Why?
|
| Peritoneal Lavage | 1 | 2012 | 21 | 0.030 |
Why?
|
| Quality Control | 2 | 2005 | 464 | 0.030 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1993 | 190 | 0.030 |
Why?
|
| HIV Core Protein p24 | 1 | 1992 | 18 | 0.030 |
Why?
|
| Temporal Bone | 1 | 1993 | 109 | 0.030 |
Why?
|
| Triazoles | 1 | 2017 | 629 | 0.030 |
Why?
|
| Cisplatin | 3 | 2006 | 2496 | 0.030 |
Why?
|
| Classification | 1 | 2011 | 40 | 0.020 |
Why?
|
| Microscopy, Interference | 1 | 2011 | 16 | 0.020 |
Why?
|
| Nitriles | 1 | 2017 | 943 | 0.020 |
Why?
|
| Maternal-Fetal Exchange | 1 | 1992 | 92 | 0.020 |
Why?
|
| Vagina | 1 | 2014 | 331 | 0.020 |
Why?
|
| Dilatation and Curettage | 1 | 2011 | 8 | 0.020 |
Why?
|
| Aspergillosis | 1 | 1993 | 249 | 0.020 |
Why?
|
| China | 1 | 2013 | 643 | 0.020 |
Why?
|
| Receptors, Steroid | 1 | 2013 | 356 | 0.020 |
Why?
|
| Cell Survival | 2 | 2011 | 3074 | 0.020 |
Why?
|
| Cell Death | 1 | 2013 | 688 | 0.020 |
Why?
|
| Cholestasis | 1 | 1993 | 206 | 0.020 |
Why?
|
| Mixed Tumor, Mullerian | 1 | 2011 | 38 | 0.020 |
Why?
|
| Mice | 4 | 2020 | 35996 | 0.020 |
Why?
|
| Genotyping Techniques | 1 | 2011 | 157 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 338 | 0.020 |
Why?
|
| Cell Dedifferentiation | 1 | 2011 | 101 | 0.020 |
Why?
|
| Pancreatitis | 1 | 1993 | 292 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2011 | 209 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 2311 | 0.020 |
Why?
|
| beta Catenin | 2 | 2006 | 690 | 0.020 |
Why?
|
| Feasibility Studies | 2 | 2009 | 2347 | 0.020 |
Why?
|
| Benzimidazoles | 1 | 2013 | 441 | 0.020 |
Why?
|
| Glycosylation | 1 | 2010 | 232 | 0.020 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2011 | 152 | 0.020 |
Why?
|
| Gene Expression | 2 | 2009 | 3678 | 0.020 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2001 | 1735 | 0.020 |
Why?
|
| Endothelium | 1 | 2010 | 162 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2011 | 1656 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2010 | 209 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 3391 | 0.020 |
Why?
|
| Groin | 2 | 2003 | 78 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2011 | 539 | 0.020 |
Why?
|
| Retinoblastoma Protein | 1 | 2011 | 342 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2011 | 753 | 0.020 |
Why?
|
| Biomarkers | 3 | 2012 | 5105 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 7216 | 0.020 |
Why?
|
| Choriocarcinoma | 1 | 2009 | 49 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2011 | 356 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2012 | 1567 | 0.020 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2009 | 107 | 0.020 |
Why?
|
| Computer Simulation | 2 | 2005 | 1522 | 0.020 |
Why?
|
| Alphapapillomavirus | 1 | 2010 | 174 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2011 | 496 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2020 | 12198 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 1085 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 1084 | 0.020 |
Why?
|
| Pyrazines | 1 | 2011 | 513 | 0.020 |
Why?
|
| Adenoma | 1 | 1993 | 742 | 0.020 |
Why?
|
| Northern Ireland | 1 | 2007 | 4 | 0.020 |
Why?
|
| Thyroid Nuclear Factor 1 | 1 | 2007 | 52 | 0.020 |
Why?
|
| Placenta | 1 | 1992 | 565 | 0.020 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2008 | 57 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2012 | 1729 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2010 | 812 | 0.020 |
Why?
|
| Registries | 1 | 2015 | 2238 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2010 | 729 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2007 | 3537 | 0.020 |
Why?
|
| Mitosis | 1 | 2009 | 691 | 0.020 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2006 | 64 | 0.020 |
Why?
|
| Radiotherapy | 2 | 2006 | 1858 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 5902 | 0.020 |
Why?
|
| Medical Records | 1 | 2007 | 445 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2007 | 351 | 0.020 |
Why?
|
| Discriminant Analysis | 2 | 1996 | 53 | 0.020 |
Why?
|
| Colposcopes | 1 | 2005 | 2 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2009 | 686 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2006 | 169 | 0.020 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2006 | 147 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2006 | 112 | 0.020 |
Why?
|
| Human papillomavirus 16 | 1 | 2007 | 256 | 0.020 |
Why?
|
| Diverticulum | 1 | 2005 | 37 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2011 | 14854 | 0.020 |
Why?
|
| Antigen Presentation | 1 | 2006 | 289 | 0.020 |
Why?
|
| Suction | 1 | 2005 | 111 | 0.020 |
Why?
|
| Sialoglycoproteins | 1 | 2005 | 152 | 0.020 |
Why?
|
| Imidazoles | 1 | 2011 | 1055 | 0.020 |
Why?
|
| MutS Homolog 3 Protein | 1 | 2004 | 12 | 0.020 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2010 | 1011 | 0.020 |
Why?
|
| Lewis X Antigen | 1 | 2004 | 41 | 0.020 |
Why?
|
| Osteopontin | 1 | 2005 | 146 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1997 | 2415 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2013 | 4982 | 0.020 |
Why?
|
| Colonoscopy | 1 | 2008 | 519 | 0.020 |
Why?
|
| Molecular Biology | 1 | 2006 | 182 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2013 | 13365 | 0.020 |
Why?
|
| Cyclophosphamide | 2 | 2006 | 3231 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2006 | 441 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 2483 | 0.010 |
Why?
|
| DNA | 2 | 2003 | 3078 | 0.010 |
Why?
|
| Corpus Luteum | 1 | 2004 | 32 | 0.010 |
Why?
|
| Tissue Fixation | 1 | 2004 | 139 | 0.010 |
Why?
|
| Probability | 2 | 1996 | 876 | 0.010 |
Why?
|
| Vacuum | 1 | 2003 | 42 | 0.010 |
Why?
|
| Frameshift Mutation | 1 | 2004 | 234 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 2084 | 0.010 |
Why?
|
| Enterotoxins | 1 | 2004 | 122 | 0.010 |
Why?
|
| Spectrometry, X-Ray Emission | 1 | 2003 | 8 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2006 | 860 | 0.010 |
Why?
|
| Flavin-Adenine Dinucleotide | 1 | 2003 | 12 | 0.010 |
Why?
|
| Finite Element Analysis | 1 | 2003 | 54 | 0.010 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2003 | 74 | 0.010 |
Why?
|
| alpha-Fetoproteins | 1 | 2004 | 256 | 0.010 |
Why?
|
| Bandages | 1 | 2003 | 80 | 0.010 |
Why?
|
| Perineum | 1 | 2003 | 116 | 0.010 |
Why?
|
| Optical Fibers | 1 | 2003 | 38 | 0.010 |
Why?
|
| Infant | 2 | 1996 | 13873 | 0.010 |
Why?
|
| Particle Size | 1 | 2003 | 187 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2004 | 253 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 2003 | 197 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2002 | 7786 | 0.010 |
Why?
|
| Skin Transplantation | 1 | 2003 | 185 | 0.010 |
Why?
|
| Lip | 1 | 2002 | 35 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2003 | 734 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 2003 | 257 | 0.010 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2005 | 532 | 0.010 |
Why?
|
| Mastectomy | 1 | 2009 | 1547 | 0.010 |
Why?
|
| Thyroid Neoplasms | 1 | 1993 | 1882 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2002 | 14 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2003 | 307 | 0.010 |
Why?
|
| Genome, Human | 1 | 2010 | 1833 | 0.010 |
Why?
|
| Cheilitis | 1 | 2001 | 4 | 0.010 |
Why?
|
| Principal Component Analysis | 1 | 2002 | 219 | 0.010 |
Why?
|
| Photosensitivity Disorders | 1 | 2001 | 22 | 0.010 |
Why?
|
| Light | 1 | 2003 | 280 | 0.010 |
Why?
|
| Photobiology | 1 | 2001 | 4 | 0.010 |
Why?
|
| Antigens, Bacterial | 1 | 2004 | 374 | 0.010 |
Why?
|
| Ovarian Cysts | 1 | 2001 | 41 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2006 | 1401 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2002 | 406 | 0.010 |
Why?
|
| Medical Futility | 1 | 2001 | 56 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2004 | 481 | 0.010 |
Why?
|
| Veins | 1 | 2002 | 166 | 0.010 |
Why?
|
| Omentum | 1 | 2002 | 107 | 0.010 |
Why?
|
| Fertility | 1 | 2004 | 347 | 0.010 |
Why?
|
| Tumor Virus Infections | 1 | 2002 | 249 | 0.010 |
Why?
|
| 17-alpha-Hydroxyprogesterone | 1 | 2000 | 7 | 0.010 |
Why?
|
| Linear Models | 1 | 2004 | 1092 | 0.010 |
Why?
|
| 12E7 Antigen | 1 | 2000 | 11 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2003 | 474 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2007 | 2285 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 2004 | 890 | 0.010 |
Why?
|
| Mucins | 1 | 2001 | 288 | 0.010 |
Why?
|
| Arteries | 1 | 2002 | 294 | 0.010 |
Why?
|
| Myoglobin | 1 | 2000 | 118 | 0.010 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2001 | 178 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2001 | 453 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2002 | 641 | 0.010 |
Why?
|
| Pelvic Pain | 1 | 2000 | 47 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 1439 | 0.010 |
Why?
|
| Antigens, CD20 | 1 | 2000 | 207 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2004 | 1180 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2000 | 182 | 0.010 |
Why?
|
| HIV Infections | 1 | 1992 | 2155 | 0.010 |
Why?
|
| CD3 Complex | 1 | 2000 | 320 | 0.010 |
Why?
|
| Exanthema | 1 | 2001 | 210 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 2003 | 692 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2003 | 1690 | 0.010 |
Why?
|
| Inflammation | 1 | 2009 | 2525 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2005 | 2617 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 4327 | 0.010 |
Why?
|
| Sezary Syndrome | 1 | 2000 | 167 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 1610 | 0.010 |
Why?
|
| Spectrum Analysis, Raman | 1 | 1998 | 43 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2000 | 410 | 0.010 |
Why?
|
| Monte Carlo Method | 1 | 2001 | 697 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 4962 | 0.010 |
Why?
|
| Base Sequence | 1 | 2004 | 5484 | 0.010 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2002 | 685 | 0.010 |
Why?
|
| Benzamides | 1 | 2003 | 1882 | 0.010 |
Why?
|
| Transfection | 1 | 2003 | 3164 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2002 | 896 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2009 | 7927 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2001 | 681 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 6767 | 0.010 |
Why?
|
| Recurrence | 1 | 2005 | 4882 | 0.010 |
Why?
|
| Mycosis Fungoides | 1 | 2000 | 335 | 0.010 |
Why?
|
| Metaplasia | 1 | 1998 | 386 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 2000 | 357 | 0.010 |
Why?
|
| Dactinomycin | 1 | 1996 | 163 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 4386 | 0.010 |
Why?
|
| Contrast Media | 1 | 2003 | 1510 | 0.010 |
Why?
|
| United States | 1 | 2013 | 15994 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 1965 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2003 | 1842 | 0.010 |
Why?
|
| Smoking | 1 | 2005 | 2427 | 0.010 |
Why?
|
| Software | 1 | 2003 | 1360 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2004 | 3415 | 0.010 |
Why?
|
| Nocardia asteroides | 1 | 1995 | 4 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 1995 | 259 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 1997 | 988 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2009 | 5415 | 0.010 |
Why?
|
| Injections, Intradermal | 1 | 1994 | 51 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1997 | 621 | 0.010 |
Why?
|
| Aging | 1 | 2002 | 1574 | 0.010 |
Why?
|
| Piperazines | 1 | 2003 | 2151 | 0.010 |
Why?
|
| Peptides | 1 | 2000 | 1525 | 0.010 |
Why?
|
| Translocation, Genetic | 1 | 2000 | 1287 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2006 | 3929 | 0.010 |
Why?
|
| Hyoid Bone | 1 | 1993 | 8 | 0.010 |
Why?
|
| Leg | 1 | 1995 | 216 | 0.010 |
Why?
|
| Lymphoma, B-Cell | 1 | 2000 | 935 | 0.010 |
Why?
|
| Cystectomy | 1 | 1997 | 632 | 0.010 |
Why?
|
| Phenotype | 1 | 2004 | 6452 | 0.010 |
Why?
|
| Cell Division | 1 | 1997 | 2711 | 0.010 |
Why?
|
| Forecasting | 1 | 1996 | 705 | 0.010 |
Why?
|
| Methotrexate | 1 | 1996 | 1027 | 0.010 |
Why?
|
| Intraoperative Care | 1 | 1994 | 274 | 0.010 |
Why?
|
| Life Style | 1 | 1996 | 618 | 0.010 |
Why?
|
| Vincristine | 1 | 1996 | 1572 | 0.010 |
Why?
|
| Trachea | 1 | 1994 | 290 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2000 | 5775 | 0.010 |
Why?
|
| Tracheostomy | 1 | 1994 | 247 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1995 | 1616 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2003 | 3664 | 0.010 |
Why?
|
| Preoperative Care | 1 | 1995 | 1550 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 1995 | 2118 | 0.000 |
Why?
|